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The proliferation and differentiation of normal prostate epithelial cells depend
upon the action of the androgens, testosterone and dihydrotestosterone. Prostate cancer
cells retain the ability to respond to androgens in the initial stages of cancer development
but progressively become independent of exogenous androgens in advanced stages of the
disease while maintaining the expression of functional androgen receptor (AR). We
hypothesized that prostate cancer cells in the advanced stages of the disease acquire
capability to synthesize androgens which activate AR in an intracrine manner. To test
this hypothesis, we determined the expression of proteins and enzymes involved in
cholesterol uptake, transport and its conversion into testosterone in androgen-dependent
and androgen-independent prostate cancer cell lines. Established androgen independent
prostate cancer cell lines, PC3 and DU145 cells, expressed mRNA and proteins for
scavenger receptor type B 1 (SRB 1), steroidogenic acute regulatory (StAR) protein,
metastatic lymph node 64 (MLN64), cytochrome P450 cholesterol side chain cleavage
(CYP11), and other enzymes involved in androgen biosynthesis. Expression of all these
proteins and enzymes was significantly higher in the androgen-independent derivative of
LNCaP prostate cancer cells (C8 1) than in the androgen-dependent cell line (C3 3). In
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serum free cultures, the androgen independent cell line C8 1 secreted ~5 fold higher
testosterone than C33 as determined in the conditioned media by specific immunoassays.
These cells also converted radioactive cholesterol into testosterone which was identified
by thin layer chromatography. To evaluate the effects of endogenous production of
testosterone on the survival and growth of prostate cancer cells, C8 1 cells were treated
with either aminoglutethimide to prevent conversion of cholesterol to pregnenolone or
the AR antagonist, bicalutamide. Our results demonstrated growth inhibition ofC8l cells
and a reduction in expression of the AR regulated genes, PSA and TMPRSS2 in
aminoglutethimide and bicalutaniide treated cells which were reversed by exogenous
androgens. These results indicate that prostate cancer cells in advanced stages of the
disease synthesize androgens from cholesterol. These androgens activate AR in an
intracrine maimer to regulate cell survival and proliferation. The ability of the prostate to
synthesize androgens may be associated with progression to castration resistant prostate
cancer and possibly represents a therapeutic target for advanced disease.
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Prostate cancer is the most frequently diagnosed cancer in men and is the second
leading cause of cancer death of men in the United States (Jemal et al. 2008). The
American Cancer Society estimated that 186,320 new cases of prostate cancer were
diagnosed and 28,660 men died from the disease in 2008 (Jemal et al. 2008). Increased
prostate cancer screening and improved surgical and radiologic treatments have led to
decreased prostate cancer mortality rates during the past 10 years. However, as many as
twenty percent of patients diagnosed with prostate cancer present with metastatic disease
or develop metastases following treatment (Taichman et al. 2007). Currently, there is no
effective treatment for metastatic disease making it the most common cause of death
from prostate cancer. Several risk factors including age (Scardino, Weaver and Hudson
1992), ethnicity (Glover et al. 1998; Gueye et al. 2003; Powell 2007), and family history
(Steinberg et al. 1990; Spitz et al. 1991; Lesko, Rosenberg and Shapiro 1996) have been
associated with development of prostate cancer.
Prostate cancer is considered a disease of aging with 64% of cases diagnosed in
men 65 years of age or older (Scardino, Weaver and Hudson 1992; Jemal et al. 2008).
However, autopsies of African-American men whose deaths were not cancer related
showed evidence of high-grade prostatic intraepithelial neoplasm as early as the third
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decade of life (Sakr 1999). It has been reported that African- American men have the
highest incidence of prostate cancer with rates approximately 6000 higher than
Caucasians and they are more than twice as likely to die from the disease (Glover et al.
1998; Gueye et al. 2003; Powell 2007). Epidemiological studies have shown that men
with first or second degree relatives affected by a positive history of prostate cancer are at
greater risk of developing the disease (Lesko, Rosenberg and Shapiro 1996). It is
estimated that disease associated with a positive family history accounts for 5° o - 10% of
prostate cancers (Jemal et al. 2008). In addition to epidemiological evidence, research on
the cellular and molecular biology of prostate cancer has identified malfunctions of
steroid hormones (Huggins 1967; Culig et al. 1997; Nelson et al. 2002; Linja et al. 2001)
and other growth factors (Craft et al. 1999; Djavan et al. 2001; Gin, Ozen and Ittmann
2001; Jenster 2000; Yeh et al. 1999) that contribute to the etiology of the disease.
Androgen signaling is the primary hormonal pathway extensively investigated in
prostate cancer research (Agoulnik and Weigel 2006; Almirah et al. 2006; Brooke, Parker
and Bevan 2008; Burd, Morey and Knudsen 2006; Chen, Sawyers and Scher 2008; Culig
2003; Debes and Tindall 2002; Dehm and Tindall 2007; Ford et al. 2003; Gregory et al.
1998). The development and growth of the normal prostate gland as well as the
development of prostate cancer are dependent on the presence of androgens (Huggins
1967). Androgens are steroid hormones that are produced from cholesterol by a series of
enzymatic steps beginning with cleavage of the side chain of cholesterol to form the
steroid, pregnenolone (Shin 1967). The principal androgen, testosterone, is synthesized in
males primarily by Leydig cells of the testes (Shin 1967; Payne and Youngblood 1995).
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It is converted to the more potent androgen, 5ct-dihydrotestosterone (DHT), in the
prostate by 5ct-reductase through the addition of two hydrogen atoms to its structure and
removal of the carbon 4-5 double bond (Andersson, Bishop and Russell 1989; Andersson
and Russell 1990). The resulting structure of DHT enhances its ability to bind to the
androgen receptor (AR) in the target cells (Silver et a!. 1994). Both testosterone and
DHT exert their biological effects through their binding to AR (Trapman and Brinkman
1996; Gelmann 2002). AR is a member of the nuclear receptor superfamily and a ligand
activated transcription factor (Trapman and Brinkman 1996; Gelmann 2002). When AR
is not bound to androgen it is found in the cytoplasm associated with heat-shock proteins
that prevent it from translocating to the nucleus (Trapman and Brinkman 1996). Upon
ligand binding AR dissociates from the heat-shock proteins and translocates to the
nucleus where it recruits cofactors for stimulation of transcriptional activity (Trapman
and Brinkman 1996). Genes regulated by AR have been shown to be involved in prostate
growth and differentiation (Bolton et al. 2007).
The majority of prostate cancers are dependent on androgens at initial diagnosis;
therefore endocrine therapy is directed toward reduction of serum androgens and/or
inhibition of AR (Huggins 1967). Although androgen ablation causes regression of
androgen-dependent tumors, a major challenge for prostate cancer management is the
progression of the disease to a castration resistant state. There is currently no therapy
available to treat these androgen independent tumors, and the patient will eventually die
from the disease. A logical assumption is that cancer cells in later stages of the disease
have acquired the potential to survive and proliferate in the absence of exogenous
4
testosterone. This is achieved presumably via production of growth factors, cytokines,
and other molecules which regulate these functions (Hughes et al. 2005). A large number
of studies have shown that as prostate tumors become androgen independent, a number of
cellular pathways, some involving AR and others bypassing it, support tumor growth
(Pienta and Bradley 2006; Debes and Tindall 2004).
AR is expressed throughout prostate cancer progression, and studies have shown
that the majority of androgen independent tumors still express AR (Gelmann 2002; Titus
2005). Studies of gene expression in prostate tumors from patients with recurrent prostate
cancer have found that the AR is consistently upregulated and this amplified AR is of the
wild type (Chen et al. 2004; Koivisto et al. 1997). Increased AR mRNA expression is a
possible mechanism that allows prostate cancer cells to survive in a castration level
androgen environment (Gelmann 2002).
A number of mutations of the AR gene have also been reported to be associated
with androgen insensitivity (Hsing et al. 2002; Hiort et al. 1996). These mutations can
cause various malfunctions in androgen signaling. Mutations in the ligand binding
domain of the AR appear to reduce ligand specificity (Gelmann 2002), and may also
cause the conversion of AR antagonists to agonists (Heinlein and Chang 2004; Brooke
and Bevan 2008). Mutations of the AR are rare in early stages of prostate cancer, but
their incidence increases significantly after androgen ablation and subsequent transition
to androgen independence, suggesting that mutations are important in disease progression
(Heinlein and Chang 2004; Brooke and Bevan 2008).
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Growth factors, such as insulin like growth factor-i (Culig et al. 1994),
interleukin-6 (Hobisch et al. 1998), keratinocyte growth factor (Reinikainen, Palvimo
and Janne 1996), and epidermal growth factor (Weigel and Zhang 1998) have been
shown to be overexpressed in some cases of prostate cancer and are responsible for
ligand-independent activation of the AR (Jenster 2000; Hughes et a!. 2005). There is
evidence to suggest that in some cases upregulation of parallel pathways can provide a
substitute survival signal that allows the cancer to bypass the reliance upon the AR
pathway (Brooke and Bevan 2008). In contrast however, inhibition of AR expression in
androgen independent prostate cancer cells has been shown to result in restriction of
growth of these cells suggesting the essential role of AR in cell proliferation (Chen et al.
2004).
The possibility that prostate cancer cells may acquire steroidogenic potential and
may produce steroids which bind AR and stimulate gene expression has also been
explored by many investigators. Mohier et a!. (2004) reported that tissue androgens are
present in recurrent prostate cancers at levels sufficient for androgen receptor activation.
Several other studies have addressed the potential of prostate cells to synthesize and
metabolize androgens from other steroid precursors (Stanbrough et al. 2006; Nakamura et
al. 2005). Steroidogenic enzymes, 1 7beta-hydroxysteroid dehydrogenase (1 713-HSD), 3
beta-hydroxysteroid dehydrogenase (313-HSD), CYP1 1, and aromatase, which converts
androgens to estrogens, have been found to be localized in prostate tissues (El-Alfy et al.
1999; Ellem et al. 2004). Increased expression of genes involved in cholesterol
biosynthesis from acetate has also been reported in prostate carcinoma during hormone
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ablation therapy (Holzbeierlein et al. 2004). On the basis of these studies, it has been
postulated that prostate cancer cells are capable of converting plasma steroid precursors
into androgens and estrogens which may then serve as ligands for their respective
receptors and regulate gene expression in these cells. The possibility that prostate cells
may acquire the capability to convert cholesterol into androgens and estrogens has not
been investigated.
The studies reported here were undertaken to investigate whether the acquisition
of androgen independence in prostate cancer cell lines correlates with the expression of
cellular proteins and enzymes involved in cholesterol uptake, its transportation to the
inner mitochondrial membrane and its conversion into testosterone indicating that these
cells contain all components needed to synthesize testosterone (figure 1) which, in turn,

















Figure 1. Testosterone Biosynthesis Pathway.
We hypothesized that prostate cancer cells in advanced stages of the disease
acquire the ability to synthesize testosterone from cholesterol and that endogenously
produced androgen acting via AR is necessary for survival and proliferation of prostate
cancer cells. To test this hypothesis, the following aims were investigated:
1. To determine the expression in prostate cancer cell lines of the functional
components necessary for androgen biosynthesis from cholesterol.
2. To investigate the effect of endogenous androgen production on proliferation and
survival of prostate cancer cells and determine whether the actions of endogenous
steroids are mediated via the AR.
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At the conclusion of these studies, we have demonstrated for the first time that
prostate cancer cells in advanced stages of disease acquire the ability to synthesize
testosterone from cholesterol and hence are not dependent upon testicular or adrenal
androgens for survival and proliferation (Dillard, Lin, and Khan 2008). Also,
endogenously synthesized testosterone is required for survival and proliferation of
prostate cancer cells and these actions are mediated by the AR (Dillard et al. unpublished
data). Although androgen ablation therapy directed at eliminating sources of exogenous
testosterone is the current mainstay of treatment, the results of this study suggest that
endogenous prostate androgen biosynthesis may represent a potential therapeutic target in
the treatment of advanced prostate cancer.
CHAPTER 2
REVIEW OF THE LITERATURE
Growth and Development of the Prostate Gland
The prostate gland is an accessory organ of the male reproductive system located
at the base of the bladder surrounding the urethra that functions to secrete components of
seminal fluid (Cunha et a!. 1987; Jost 1973). During the early phase of embryogenesis,
preceding sexual differentiation into male or female, the internal genitalia is comprised of
the mullerian and woiffian ducts, mesonephric tubules, and the urogenital sinus (Cunha
1986). The male urogenital tract develops from the woiffian duct which gives rise to the
epididymis, ductus deferens, seminal vesicle, and ejaculatory duct; and, the urogenital
sinus from which the prostate, bulbourethral glands, urethra, and periurethral glands
develop (Cunha 1986). Growth and development of the male accessory sexual structures
are androgen dependent (Cunha et a!. 1987; Jost 1973). During the ambisexual phase of
embryonic development testosterone is synthesized by the fetal testes and is converted to
DHT by the 5cL-reductase enzyme which is present in the urogenital sinus (Siiteri and
Wilson 1974). It has been demonstrated that DHT is required for prostate development
in both humans and rats (Anderson and Liao 1968; Bruchovsky and Wilson 1968).
Inhibition of 5ct-reductase in rats during fetal development results in partial development
of the prostate (Bruchovsky and Wilson 1968; Imperato-McGinley et al. 1985).
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Testosterone synthesis begins during weeks 10-12 of gestation and continues until
birth, when there is a significant reduction in testosterone levels (Pointis et al. 1980;
Resko 1978). Animal studies show that removal of fetal testes during the ambisexual
period of sexual differentiation inhibits masculinization of the wolffian duct and
urogenital sinus (Jost 1973). Similar studies have shown that treatment of animals with
anti-androgens during pregnancy inhibits the development of the prostate and other male
accessory sex glands (Neumann et al. 1970). The action of androgens during fetal
development of the male urogenital tract is mediated by androgen receptors (Cunha et al.
1991). In the morphologically undifferentiated stage of sexual development, androgen
receptors are present in the mesenchyme of the urogenital sinus but initially they are
undetectable in the epithelium of the developing male urogenital tract (Cunha et al. 1987;
Husmann et al. 1991; Takeda and Chang 1991). In spite of the absence of epithelial
androgen receptors evidence of a number of androgen regulated developmental processes
are shown to occur (Cunha et al. 1991). In tissue recombination studies using tissue from
testicular feminized (Tfm) mice that carry a loss of function mutation in the AR and
mesenchyme containing the wild type AR, researchers were able to show generation of
prostatic buds when androgens were present (Cunha and Chung 1981). In contrast, when
urogenital epithelial containing wild type AR was combined with Tfm urogenital
mesenchyme prostatic buds were not formed (Cunha and Chung 1981). These results
show that mesenchymal AR but not epithelial AR is required for generation of prostatic
tissue. It has been suggested by Cunha et al. (1991) that in prostate development,
androgens may regulate epithelial development through paracrine factors secreted by the
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mesenchyme. The importance of AR in the development of the prostate has also been
demonstrated using an AR knockout mouse model. In this model, the lack of AR
resulted in the production of animals lacking a prostate (Yeh et al. 2002).
The prostate is first observed in weeks 10-12 of gestation in humans (Zondek and
Zondek 1979), E 16.5 in mice, and E 17.5 in rats (Hayashi et al 1991; Lung and Cunha
1981; Sugimura, Cunha and Donjacour 1986). The growth and development of rat and
mouse prostates are continuous throughout animal development while in humans prostate
development involves the initial growth at 10-12 weeks of gestation followed by growth
quiescence at birth that continues throughout childhood until puberty when, concomitant
with rising androgen levels, there is renewed growth which ceases at early adulthood
(Coffey and Pienta 1987; Lung and Cunha 1981). Studies of growth patterns within the
prostate have shown that DNA synthesis is not constant throughout the gland but is more
pronounced in the ductal tips compared to proximal ductal regions (Prins et al. 1992;
Sugimura, Cunha and Donjacour 1986). Investigation of differential DNA synthesis
along the growing prostatic ducts did not show a correlation with androgen or androgen
receptor expression (Prins et al. 1992).
The prostate gland is described as having three morphologically distinct glandular
areas categorized as the peripheral, central, and transition zones (McNeal 1981). The
peripheral zone comprises 70% of the prostate volume and is the area where the majority
of prostate carcinomas develop. The central zone surrounds the urethra and the
ejaculatory ducts and accounts for 20% of the glands’ volume. The area that lies between
the peripheral and central zone is referred to as the transition zone. The prostate is made
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up of two components, epithelial and stromal. The stroma consists of mostly smooth
muscle cells and fibroblasts (Cunha and Young 1991). Studies in rats have shown that
the smooth muscle cells of the prostate stroma are AR positive but stromal fibroblasts and
endothelial cells are AR negative (Prins, Birch and Greene 1991; Hsing et al. 2002). The
epithelial cells form glands that contain luminal secretory, basal, and neuroendocrine
cells. The AR positive luminal cells secrete prostate specific antigen (PSA) as well as
prostatic acid phosphatase (PAP) and represent the more differentiated epithelial
phenotype that require androgens for survival (Prins, Birch and Greene 1991). Basal cells
are AR negative (Prins, Birch and Greene 1991; Bonkoff and Remberger 1996)) and cell
proliferation studies measuring PCNA activity show that in the normal prostate 83% of
the basal cells are PCNA positive which suggest that basal cells may be precursors of
terminally differentiated luminal cells (McNeal, Haillot and Yemoto 1995).
Androgens and Androgen Receptor Signaling
In a review by Hoberman (1995), studies involving androgens can be found
dating back as early as 1889 when a Harvard professor, Brown-Sequard injected himself
with a substance he isolated from pig and dog testicles whose effects were described as
the “elixir of life”. In 1927, University of Chicago professor, Fred Koch, isolated small
quantities of androgen from bull testicles and studied the effects in castrated roosters. It
was not until 1935 that the androgen, testosterone was synthesized in the laboratory and
this pioneering work earned Butenandt and Ruzicka the Nobel Prize in Chemistry in 1939
(Hoberman 1995). Later the identification and the cloning of AR further stimulated
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interest in androgens and their role in the prostate. Androgen signaling is the hormonal
pathway most extensively investigated in prostate gland research.
Testosterone, the major circulating androgen, is produced in Leydig cells of the
testes (Shin 1967; Payne and Youngblood 1995). Within the prostate, testosterone is
converted by 5ct-reductase to the more potent androgen (figure 2), DHT (Titus et a!.
2005). Both testosterone and DHT are steroid hormones which promote the development
of human male secondary sexual characteristics (Cunha 1987). They exhibit the four-ring
steroid backbone structure and include oxygen and hydrogen molecules within the ring
structure that distinguishes the various steroid hormones (Dorfman 1957; Piatak et al.
1964). Androgens are small hydrophobic molecules that diffuse easily across the plasma
membrane and bind to their intracellular receptor (Dorfman 1957). Both testosterone and
DHT exert their biological effects through binding to AR (Trapman and Brinkman 1996).
Testosterone (C19H2802) 5ct reductase 5 cL-dihydrotestosterone (C19H3002)
Figure 2. Testosterone conversion to DHT.
Expression of AR in the prostate was first described in 1969 (Fang, Anderson and
Liao 1969) and the cDNA for AR was cloned in 1988 (Chang, Kokontis and Liao 1988).
The AR gene is located on the X chromosome and contains 8 exons which code for
specific functional domains within the protein (Lubahn et a!. 1988). The AR protein
H
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consists of 919 amino and has a molecular weight of 110 kDa (Trapman eta!. 1988).
The AR is a member of the nuclear receptor superfamily of transcription factors (Evans
1988; O’Malley 1990). Similar to the other steroid receptors, the AR protein contains
four major functional domains: the amino-terminus regulatory domain, a DNA-binding
domain, a hinge region, and the ligand-binding domain (Jenster et a!. 1995). The
structure of the AR ligand binding domain (LBD) has been determined by
crystallography and shows that it folds into 12 helices to form a ligand binding pocket
(Sack et a!. 2001). The LBD interacts with testosterone and DHT as well as with a
number of steroidal and non-steroidal agonists and antagonists (Gao and Dalton 2007).
There are 70 amino acids contained in the DNA binding domain (DBD) which is the
most conserved region among the steroid hormone receptors (Jenster et a!. 1995). A
nucleotide blast of the DBD of human AR shows 100% homology with rats and varying
homologies with other human steroid hormones, 79% identity to progesterone receptor,
76% identity to glucocorticoid receptor, and 56% identity to estrogen receptor a. Studies
have shown that there is a great deal of homology and similarity between the DNA
binding domains and response elements of the steroid receptors respectively which
explains the promiscuity of response elements for androgen, estrogen, glucocorticoid,
progesterone and mineralocorticoid receptors (Cato et al. 1987; Ham et a!. 1988). The
hinge region serves as a linker between the LBD and DBD and it contains a nuclear
localization signal (Evans 1988). The amino-terminal domain (NTD) of AR is
responsible for the transactivation processes of transcription.
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There are several polymorphic CAG repeats in the AR gene beginning at codon
58 that can vary in length from 14 to 35 repeats (Casella et al. 2001). Epidemiological
studies have established weak correlations between the CAG repeat number and prostate
cancer risk (Casella eta!. 2001; Ferro et al. 2002). Transcription of the AR gene occurs at
two different start sites in the promoter region which permits the binding of a variety of
activators (Grossman et al. 1994; Song et a!. 1993). Prior to activation by ligand the AR
is associated with heat shock proteins and high molecular weight immunophilins that
sequester the AR in the cytoplasm. The binding of androgens to the AR results in AR
conformational change that promotes the release of chaperone proteins and facilitates
receptor nuclear translocation (figure 3). Activated AR binds DNA as a homodimer
(McEwan and Gustafsson 1997; Jenster, Trapman and Brinkman 1993) and coactivator
recruitment facilitates the initiation of transcription of AR-dependent genes
(Gnanapragasam et al 2000; Heinlein and Chang 2002; Heinlein and Chang 2004).
Prostate specific antigen (PSA) is the most well characterized of the AR target genes
(Riegman et al. 1991). Serum PSA is used as a screening test for the early detection of
prostate cancer as well as a monitor of disease progression. Another protease,
transmembrane protease serine type II (TMPRSS2) has been shown to be regulated by
androgens in the LNCaP cell model (Lin et al. 1999). Secreted protease has been
suggested to be involved in the activation of growth factors in the extracellular space
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Figure 3. Androgen Action (Feldman and Feldman 2001).
Androgen Biosynthesis and Metabolism
The synthesis of testicular testosterone is regulated by luteinizing hormone (LH)
secreted from the pituitary gland (Dufau et a!. 1983). Binding of LH to its cognate
receptor activates adenylate cyclase located in the Leydig cell plasma membrane causing
increased production of intracellular cyclic adenosine monophosphate (cAMP). These
activities represent the regulatory events for the initiation of steroidogenic pathways
leading to testosterone production in the Leydig cell (figure 4). LH is also important in
the negative regulation of testosterone levels. When circulating testosterone levels are


















Figure 4. LH stimulated testosterone production in Leydig cells (Payne and Youngblood
1995).
ultimate inhibition of enzymes required for steroidogenesis (Dufau et al. 1983; Dufau and
Catt 1978). The first step in the process by which LH stimulates androgen synthesis
involves transport of cholesterol to the mitochondria where cleavage of its side chain
occurs to form the steroid precursor, pregnenolone (Simpson, McArthy and Peterson
1978; Hall et al. 1979; Toaffet al. 1979). Cholesterol is the precursor for synthesis of all
steroid hormones including testosterone. Cholesterol is supplied to the cell either from
the cell membrane or via serum high density or low density lipoproteins (Freeman 1987;
Azhar, Leers-Sucheta and Reaven 2003). Cholesterol can also be synthesized de novo
from acetate in cells (Siperstein 1970). In experiments using MA-b Leydig tumor cells
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and 3H cholesterol as a plasma membrane marker it was demonstrated that cells treated
with cAMP could use membrane cholesterol for steroid hormone synthesis. In this same
study, treatment of MA- 10 cells with LDL caused a decrease in surface label and, the
radioactivity that was lost from the plasma membrane was recovered as intracellular
cholesteryl esters (Nagy and Freeman 1990).
The Scavenger receptor class B type 1(SRB1) is responsible for transporting
cholesterol from the circulation to the cytoplasm of Leydig cells (Azhar and Reaven
2002). SRB1 is highly expressed in the liver and steroidogenic tissues and functions as a
cell surface HDL receptor that mediates selective cholesterol uptake (Rigotti et al. 1997).
A study by Andersen and Dietschey (1978) showed that steroidogenesis in rat adrenals
and ovaries rely primarily on the lipoprotein cholesterol pathway. MA-b Leydig tumor
cells utilize stores of free cholesterol and cholesteryl esters for steroid hormone synthesis
(Freeman and Ascoli 1982). Reaven et al. (2000) demonstrated that during normal steroid
production, Leydig cells are not dependent upon lipoprotein cholesterol; however, trophic
hormone desensitization is accompanied by increased expression of SRB 1 and uptake of
HDL-cholesterol esters. Experiments using mice with a null mutation in the SRB1 gene
showed that plasma cholesterol concentrations were significantly increased compared
with wild type mice (Rigotti et al. 1997).
The transportation of cholesterol to the mitochondria requires a two step process.
The first step involves the movement of cholesterol to the outer mitochondrial membrane
and the second step is the translocation of cholesterol from the outer to the inner
mitochondrial membrane. Movement of cholesterol to the outer mitochondrial is
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dependent upon the action of LH induced cAMP dependent protein kinase A (PKA).
PKA stimulates the activity of cholesteryl ester hydrolase which acts to release
cholesterol from lipid stores (Trzeciak and Boyd 1974). Inhibition of cholesteryl ester
hydrolase has been shown to block cholesterol translocation into the mitochondria of
MA-b Leydig tumor cells (Gocze and Freeman 1992). The metabolism of cholesterol by
cytochrome P450 side chain cleavage enzyme (CYP1 1) requires that it be transported to
the inner mitochondrial membrane (Hall 1984). The transport of cholesterol from the
outer to the inner mitochondrial membrane requires the transport protein, steroidogenic
acute regulatory (StAR) protein (Stocco 1999). StAR is a 285 amino acid protein
consisting of an N-terminal targeting sequence domain and a C-terminal domain (Stocco
2001; Jefcoate 2002). The N-terminal targeting sequence is cleaved upon entry into the
mitochondria (Arakane et al.1998; Arakane et al. 1996; Wang et al. 1998). The 30 kDa
C-terminal domain is known as the steroidogenic acute regulatory protein-related lipid
transfer (START) domain that binds cholesterol (Pointing and Aravind 1999). In
humans, START domains have been found in 15 distinct proteins (Soccio and Breslow
2003). These 15 START domain containing proteins have been classified into six
subfamilies by a multiple sequence alignment using ClustalW (Thompson et al. 1994).
The STARD1 subfamily contains StAR. The exact mechanism of StARs’ action in
cholesterol transport is not yet fully known, however, there are several models that have
been proposed (Jefcoate, McNamara and DiBartolomeis 1986; Kallen et al. 1998;
Christenson and Strauss 2001). LH stimulation of steroidogenic cells through activation
of PKA regulates de novo production of StAR (Clark Ct al. 1994; Liu et al. 1996;
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Balasubramanian et al. 1997; Pescador et al. 1996). Although most steroidogenic tissues
utilize StAR as the mechanism for inner mitochondrial cholesterol transport, the human
placenta does not express StAR (Tuckey et al. 2004). The placenta employs another
START domain containing protein, metastatic lymph node 64 (MLN64), that belongs to
the STARD3 subfamily (Tuckey et al. 2004; Thompson et al. 1994). MLN64 has a C-
terminal domain homologous to StAR that can also transport cholesterol (Tuckey et al.
2004). MLN64 was identified as a gene overexpressed in malignant breast tumors
(Tomasetto et al. 1995).
When cholesterol reaches the inner mitochondrial membrane it is acted upon by
the cytochrome P450 enzyme (CYP 11) which converts cholesterol to the precursor
steroid, pregnenolone by three sequential reactions (Katagiri, Kagawa and Waterman
1995). These reactions add two hydroxyl groups to cholesterol at C22 and C20 followed
by cleavage between the added hydroxyl groups. As a result of these reactions,
cholesterol, a 27 carbon sterol, is cleaved of its 6-carbon group side chain producing the
21-carbon steroid precursor, pregnenolone (Katagiri, Kagawa and Waterman 1995).
Tissue specific expression of enzymes determines whether progestins, androgens,
estrogens or corticosteroids will be produced from pregnenolone in the individual
steroidogenic cells (Fevold et al. 1989). Pregnenolone diffuses across the mitochondrial
membranes and is further metabolized in the endoplasmic reticulum (Fevold et al. 1989;
Payne and Youngblood 1995). Androgens are produced from pregnenolone by two
alternative pathways, A4 or A 5, depending upon the relative concentrations of 313—HSD
and CYP 17 which compete for pregnenolone (Fevold et al 1989). In the A4 pathway
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which is more prevalent in small animals such as the rat (Fevold et al. 1989; Namiki et al.
1988; Conley et al. 1992; Tremblay et al. 1994), 313—HSD converts pregnenolone into
progesterone. Progesterone is then converted first to 1 7a-hydroxyprogesterone then into
androstenedione by the actions of CYP17 (Nakajin et al. 1981). Studies have shown that
human testes make androstenedione through both the A4 and A5 pathways. In the A5
pathway CYP 17 converts pregnenolone into 1 7a-hydroxypregnenolone and DHEA
(Siiteri and Wilson 1974; Adams 1985; Labrie, Dupont and Belanger 1985; Labrie 1991).
Although the A 4 and A 5 steroidogenic pathways have different intermediate steps they
both result in the production of androstenedione. Testosterone is formed from
androstenedione via reduction at carbon-17 by 17~—HSD. Aromatization of testosterone
by CYP19 results in the formation of estradiol (Valladares and Payne 1979).
Testosterone is released into the circulation within minutes of synthesis and is
bound most often to the serum protein, sex hormone binding globulin (SHBG; Forchielli
et al. 1963; Vermeulen 1973). Only 2 to 3% of blood testosterone is found in the free or
bioavailable form which upon entering prostate cells, is immediately converted by the
enzyme 5 cL-reductase into its more active metabolite, DUT (Imperato-McGinley et al.
1974; Andersson, Bishop and Russell 1989; Andersson et al. 1991). In addition to gonads
and adrenals, the expression of StAR, P45Oscc, 3 13-HSD, CYP 17, CYP2 1, CYP 19 and,
1 713-HSD transcripts have been reported in the prostate as well as the aorta, brain, heart,
kidney, liver, lung, and pancreas (Pezzi et al. 2003; Gingras and Simard 1999).
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Prostate Cancer Development and Progression
Age (Scardino, Weaver and Hudson 1992), ethnicity (Glover et al. 1998; Gueye et
al. 2003; Powell 2007), and a positive family history of the disease (Steinberg et al. 1990;
Spitz et al. 1991; Lesko, Rosenberg and Shapiro 1996; Carter et al. 1993) are well
established risk factors associated with the development of prostate cancer (Bostwick et
al. 2004). Like all human cancers, prostate cancer arises as the result of accumulated
genomic mutations that affords a growth or survival advantage to affected cells (Hanahan
and Weinberg 2000). Prostate cancer has been characterized based on epidemiological
data into two types, hereditary and sporadic (Carter et al. 1993). Data from studies of
families prone to prostate cancer have identified several possible inherited prostate cancer
susceptibility genes including ELAC2, RNASEL, MSR1, NSB1, and CHEK2 genes in
some families (Rebbeck et al. 2000; Carpten et al. 2002; Rokman et al. 2002; Rennert et
al 2002; Casey et al. 2002; Wang et al. 2002; Xu et al. 2002; Dejager et al. 1993;
Cybulski et al. 2004). However, most of prostate cancers are sporadic and display a
complex array of etiologies that can be categorized as: risks associated with genetic
polymorphisms, tumor suppressor genes, autocrine growth factor production and,
androgen receptor signaling anomalies.
A number of polymorphisms have been implicated in increased prostate cancer
risk (Buchanan Ct al. 2001). In the N-terminal transcriptional activation domain of the
AR, polymorphic CAG and GGN repeats code for glutamine and glycine repeats
respectively (Nelson and Witte 2002). Repeats shorter than the average have been found
to be associated with a small increase in risk (Simard et al. 2002). Polymorphisms in the
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vitamin D receptor associated with different lengths of a poly A-repeat in the 3’ region
are correlated with altered prostate cancer susceptibility (Ingles et al. 1997; Correa-Cerro
et a!. 1999). A polymorphism at Ala49Thr in SRD5A2 has been linked to increased risk
for prostate cancer especially in African Americans (Makridakis et al. 1999). Another
well characterized polymorphism that occurs in the methylene tetrahydrofolate reductase
gene, A1a677Va!, has been linked to prostate cancer susceptibility (Kimura et al. 2000).
Among established tumor suppressor genes, mutant p53 and PTEN have been
shown to be involved in the progression of prostate cancer (Navone et al. 1993;
Heidenberg et al. 1995; Cairns et al. 1997; Li et a!. 1997). Losses of chromosome Lip
and lOq, where they are located, occur with moderate frequencies in advanced cancers.
Loss of one allele is accompanied by point mutations in the remaining copy of p53,
leading to its functional inactivation (Navone et al. 1993; Heidenberg et a!. 1995). Point
mutations have also been identified for PTEN (Cairns et al. 1997; Li et a!. 1997). The
Rbl gene is located at 13q14 within one of the most commonly deleted regions in
prostate cancer (Tricoli et al. 1996; Latil et a!. 1999; Yin et a!. 1999; Schmidt et a!. 2001).
Expession of the neu oncogene has also been studied in prostate cancer and found to
occur in 80% of prostate tumors (Zhau et a!. 1992). Recently a genetic rearrangement
that causes a fusion product of TMPRSS2 with the ETS family of transcription factors
has been identified (Mehra et al. 2007; Tomlins et a!. 2005; Cerveira et a!. 2006;
Mosquera et a!. 2007). These TMPRRS2-ETS fusions have been noted in 70° o of hospital
based prostate cancers (Tomlins et a!. 2007; Laxman et al. 2006; Demichelis et a!. 2007).
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The prostate gland is described as having three morphologically distinct glandular
regions categorized as the peripheral, central and, transition zones (McNeal 1981). Most
cancers develop in the peripheral zone (68%) with only a few occurring in the central
(24%) and less than 10% occur in the transitional zone (McNeal et a!. 1988). The
prostate epithelium consists of basal, luminal and neuroendocrine cells. Most of the basal
cells are AR negative and are thought to represent self-renewing stem cells that
differentiate into luminal cells that are AR positive non-proliferating cells (Litvinov, De
Marzo and Isaacs 2003; Uzgare and Isaacs 2004). A small number of basal stem cells
differentiate into neuroendocrine cells that are AR negative. The prostate epithelium is
surrounded by a fibromuscular stroma containing primarily smooth muscle cells and
fibroblasts. When AR is activated by androgen binding in stromal cells a number of
paracrine growth and survival factors are produced (Cunha, Donjacour and Sugimura
1986). Androgen receptor occupancy by its ligand within AR positive luminal cells,
however, suppresses their proliferation and instead induces differentiation (Cunha et al.
1987; Cunha, Donjacour and Sugimura 1986). In the normal prostate there is a stromal
cell dependent androgen axis (Cunha, Donjacour and Sugimura 1986; Gao, Arnold and
Isaacs 2001). Transformation to a malignant phenotype involves a shift from this
paracrine axis to a situation in which AR signaling directly activates the production of
autocrine growth and survival factors by the prostate cancer cells themselves as well as
regulates the production of secretory proteins by these malignant cells (Gao, Arnold and
Isaacs 2001). Thus androgen acts in an autocrine manner as the major regulator of
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proliferation and survival in such androgen responsive prostate cancer cells (Litvinov et
al. 2003).
Several growth factors including IGF-1, IL-6, and TGFI3 have been implicated in
regulation of prostate cancer cell proliferation. A number of studies have linked IGF- 1 to
prostate cancer (Pollak, Beamer and Zhang 1998; Djavan et al. 2001), including an in
vivo study demonstrating that IGF- 1 increases proliferation of prostate cancer cells,
whereas inhibition of IGF-1 receptor expression suppresses in vivo tumor growth
(Burfeind et al. 1996). IL-6 was first observed by Twillie et al. (1995) to be elevated in
the sera from patients with advanced prostate cancer. Since that time additional evidence
supporting (Gin, Ozen and Ittmann 2001; Chung et al. 2000) and contradicting (Mori,
Murakami, and Bonavida 1999) the role of IL-6 in prostate cancer have been reported. A
recent research study shows that DHT can inhibit the ability of prostate cancer cells to
undergo TGF-~3 induced apoptosis by decreasing the level of TGF-13 receptor II (Song et
al. 2008).
The idea that other sex hormones contribute to the progression of prostate cancer
has also been investigated. There is epidemiological data reporting that serum
testosterone levels in black women are 40% higher than in white women during
pregnancy, and estradiol levels are 30% higher suggesting a possible link to the higher
incidence of prostate cancer in African-American men (Henderson et al. 1988). Others
have reported that exposure to maternal estrogens during fetal life leads to development
of squamous metaplasia in the fetal prostate (Driscoll and Taylor 1980). Studies have
also linked the lower prostate cancer incidence rates among Japanese and Chinese men to
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significantly reduced 5cL-reductase activity in the prostate (Titus et al. 2005). Since
receptors for androgen, estrogen and progesterone are present in the prostate, it can be
assumed that all these hormones affect prostate growth.
Growth of the prostate during development and the function of the prostate at
maturity are dependent on androgens (Cunha et al. 1987). As indicated previously
studies have shown that during puberty, concomitant with increased production of
testosterone, there is rapid prostate growth that ceases at early adulthood (Cunha,
Donjacour and Sugimura 1986). In prostate cancer and benign prostatic hyperplasia,
androgen dependent growth resumes (McNeal 1981). In a well known study it has been
demonstrated that eunuchs lack many of the male characteristics associated with
androgens and do not develop prostate cancer (Huggins 1967). Studies by Schaeffer et al.
(2008) demonstrated that AR signaling controls epithelial cell development and function
in embryogenesis by the same process that is involved in cancer development. They
confirmed that early androgen exposure in the mouse prostate rudiment induced
proliferation and invasion of prostate epithelial buds into the surrounding urogenital sinus
mesenchyme. They also showed that this early androgen exposure regulated a number of
genes that have been implicated in prostate carcinogenesis.
AR signaling has been implicated in the transformation of prostate epithelial cells
to a malignant phenotype. It has been suggested that AR signaling in prostate cancer
cells shifts from paracrine to autocrine production of growth and survival factors (Gao et
al. 2001). The molecular mechanisms underlying prostate cancer initiation and
progression to metastatic disease are poorly understood. Because the human prostate is
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an androgen-dependent organ, it is logical to presume that prostate malignancy develops
under abnormal androgenic stimulation. There is a preponderance of evidence showing
that AR is present in primary site and metastatic prostate cancer regardless of stage and
grade (Culig et al. 2000; de Winter et al. 1990; Trapman and Cleutjens 1997). AR
activation in androgen-responsive prostate cancer has been demonstrated to elicit a
plethora of events including proliferation, apoptosis, and angiogenesis which together
control prostate cancer growth (Matsushima et al. 1999). The AR regulated gene, PSA,
is an important biomarker for prostate cancer development and progression (Heinlein and
Chang 2004). Gene expression profiling studies have shown that as many as 4% of genes
expressed in prostate cancer are regulated by androgens (Heinlein and Chang 2004).
Holzbeierlein et al. (2004) performed a genome-wide analysis of prostate cancer tissue
during hormone deprivation therapy and demonstrated that only androgen responsive
genes showed modulation during 3 months of androgen ablation, suggesting the
involvement of AR.
Androgen ablation therapy is the standard treatment for advanced prostate cancer.
There are several forms of endocrine therapy currently in use, primary therapy is directed
toward removal of testicular androgens and includes; surgical castration or medical
castration with estrogens (DES), GnRH analogs, flutamide, or ketoconazole (Grayhack,
Keeler and Kozlowski 1987). Although initially successful at blocking tumor growth,
these therapies eventually fail, and the disease advances to a castration resistant stage
which usually results in patient death.
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Hormone Refractory Prostate Cancer
Prostate cancers that are able to survive and proliferate in spite of castration levels
of testosterone in the blood have been categorized as castration resistant (Mohier et al
2004). Advancement to this aggressive stage of the prostate cancer is accompanied by a
rise in PSA along with progression to metastatic disease (Feldman and Feldman 2001).
There are a number of mechanisms that have been associated with recurrent prostate
cancer most of which involve the presence and activity of the AR (Craft et al. 1999;
Heinlein and Chang 2004; Chlenski et al. 2001; Culig Ct a!. 2000; Chen et al. 2004).
Several studies have reported the expression of the AR gene in androgen
independent cancers (Agoulnik and Weigel 2006; Chen et al. 2004; Chlenski eta!. 2001;
Craft et al. 2009; Culig et a!. 2000; Edwards et al. 2003). Gene expression analysis of
tissue samples from patients with recurrent disease following androgen ablation therapy
showed gene expression patterns similar to untreated, androgen-dependent tumors
(Holzbierlein et al. 2004). In this study there was a marked increase in the level of AR
mRNA by microarray and immunohistochemical analysis also demonstrated a high level
of AR protein expression.
It has been shown that the AR gene plays a critical role in the pathogenesis and
tumor progression of prostate cancer (Agoulnik et al. 2006; Chelenski et al. 2001; Craft et
al. 1999). Amplification of AR is one mechanism proposed that may explain the ability
of prostate cancer cells to survive in a castration level androgen environment (Edwards et
al. 2003; Ford et al. 2003; Haapala et al. 20007). It is reported that 20% to 30% of
androgen-independent prostate cancers have increased AR levels (Visakorpi et al. 1995).
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In xenograft models of several prostate cancer cells, upregulation of AR has been
demonstrated to be the only consistent change (Chen et al 2004). In experiments in
which wild type AR was overexpressed in LNCaP cells there was a conversion of the AR
antagonist, bicalutamide to an agonist; this action was suggested to be due to an
overabundance of AR compared to corepressors which could lead to the inappropriate
binding of AR to coactivators instead. This phenomenon has been illustrated in ChIP
experiments in wild type-AR overexpressing LNCaP cells. At the promoters of PSA and
KLK-2 in these cells, the transcription complex consisted of more coactivators than
corepressors in the presence of bicalutamide (Chen et al. 2004). Investigations in animal
models have shown that increased AR expression can be accompanied by increased
receptor stability and enhanced nuclear localization (Gregory et al. 2001). In CWR-R1
and C4-2 androgen independent cell lines expressing high levels of AR it has been shown
that they require 4 fold less DHT than androgen dependent LNCaP cells (Horoszewicz et
al. 1983). A study of the expression level of AR in androgen —dependent and
independent prostate cancer using real-time quantitative PCR showed that all androgen
independent tumors expressed 6 fold higher AR compared with androgen dependent
tumors (Linja et a!. 2001). These findings suggest that high levels of AR may allow
prostate cancer cells to proliferate in response to low levels of androgen following
androgen ablation therapy.
Somatic mutations in the AR, many of which are located in the LBD, have been
reported in recurrent prostate cancers (Gottlieb et a!. 1999). Mutations of the AR are rare
in early stages of prostate cancer, but their incidence have been found to increase
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significantly after androgen ablation therapy and the progression to castration resistant
disease (Taplin et al. 1995). In a study involving a large sample of prostate cancer
patients with early stage disease, none of them were found to have mutations in the
coding region of AR. However, 21% of patients with more advanced disease were found
to have mutant forms of AR (Marcelli et al. 2000). Many of these mutants have been
shown to allow alternative ligands such as, other hormones and antiandrogens, to bind
and activate the receptor which would provide a growth advantage by reducing ligand
specificity. The first AR mutation with loss of ligand specificity to be described was the
T877A substitution (Veldscholte et al. 1992) which is also shown to be present in the
LNCaP prostate cancer cell line and is frequently found in advanced prostate carcinomas
(Gaddipati et al. 1994; Gottlieb et al. 1999; Taplin et al. 1995; Taplin et al. 1999).
Studies of the T877A mutation in LNCaP has shown effects ranging from activation of
the AR by the hormones, estrogen and progesterone as well as the AR antagonists,
cyproterone acetate and hydroxyflutamide (Veldscholte, Berrevoets, and Mulder 1994),
however, bicualutamide is able to block AR target gene transcription and cell growth
(Berrevoets et al. 1993).
A number of investigations have provided evidence that AR can be activated by
cytokines and other growth factors such as IGF-1, EGF, KGF, and IL-6 which are
produced by prostatic stromal or epithelial cells (Culig et al. 1994; Hobisch et al. 1998;
Lin et al. 2001). IGF-1 was shown to be able to induce a 5 fold increase in PSA
expression in LNCaP cells and this activity could be blocked by the AR antagonist,
bicalutamide (Culig et al. 1994). HER2/Neu (erbB2), a member of the EGF receptor
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family, has been demonstrated to increase growth rate, PSA level, and AR transactivation
in prostate cancer cells via the MAP kinase pathway (Uzgare and Isaacs 2004).
HER2/Neu activated AR transactivation occurs without addition of exogenous androgens
(Yeh et al. 1999).
In a study in which tissues levels of testosterone and DHT were measured in
eighteen men with recurrent prostate cancer and eighteen men with androgen sensitive
benign prostates who received no hormone therapy it was noted that testosterone levels
were similar among the two groups, however DHT levels were 91% lower in recurrent
prostate cancer after a median of 37 months (Titus et al. 2005). This reduced level of
DHT was found to be sufficient to activate the androgen receptor based on studies of
prostate cancer cell lines (Culig et al. 1999; Gregory et al. 2001). It was postulated based
on the findings of this and other studies that testosterone and DHT in recurrent prostate
cancer tissue may result from intracrine metabolism of circulating adrenal androgens
(Titus et al. 2005; Harper et al. 1974). In another study, gene expression in 33 androgen
independent prostate cancer bone metastases versus 22 laser capture microdissected
primary prostate cancers were compared using microarrays. In the androgen independent
prostate cancer bone metastases many of the androgen-regulated genes were decreased 2
to 3 fold, nonetheless, there were key androgen-regulated transcripts that were
upregulated including PSA, KLK2, and NKX3.1 (Stanbrough et al. 2006). AR
expression was also increased in the majority of androgen-independent tumors. This
finding is consistent with other reported studies showing AR amplification (van der
Kwast et al. 1991; Visakorpibet al. 1995; Taplin et al. 1995; Holzbeierlein et al. 2004).
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In this same study several genes involved in androgen synthesis, 1713-HSD, 5o~-
reductase 1 and, 3 f3-HSD2 were upregulated. These investigators as did Titus et al. (2005)
attributed the increased expression of the genes involved in androgen metabolism to
enhanced conversion of adrenal androgens, DHEA and androstenedione, to testosterone
and DHT. Nakamura et al. (2005) evaluated the immunoreactivites of 5 a-reductase
types 1 and 2 and 17~3-HSD5 in 70 prostate cancers obtained from surgery. In 77% of the
cases 17~3-HSD5 was detected and 73% and 56%, respectively for 5ct-reductase type 1
and type 2. A study of expression profiles of androgen ablation-resistant tumors
demonstrated the upregulation of AR and key enzymes for cholesterol biosynthesis
(Holzbeierlein et al. 2004). Immunocytochemistry analysis of human prostate tissue has
shown the presence of both 3f3-HSD and 1713-HSD in epithelial cells (El-Alfy et a!.
1999). Both aromatase protein and message have been identified in the human prostate,
suggesting local aromatization could provide a source of estrogen in the prostate (Ellem
et al. 2004). These studies collectively suggest that the local synthesis of androgens from
adrenal precursors may play a role in prostate cancer cell survival and proliferation in a
castration level androgen environment.
Prostate Cancer in vitro and in vivo Models
Several prostate cancer cell lines have been established to study the molecular and
cellular mechanisms involved in the development and progression of the disease.
Various cell lines differ with regards to characteristics however, and can represent
different stages of prostate cancer (van Bokhoven et al. 2003). A literature search reveals
that the majority of in vitro prostate cancer research has employed the use of three cell
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lines, LNCaP, DU145 and PC3. LNCaP cells were isolated from a human prostate
cancer lymph node metastasis, are CK5-negative and CK8/1 8-positive (van Bokhoven et
al. 2003). LNCaP cells express a mutant AR (T877A) and respond to androgens/AR
signals differentially depending on the passage number and culture conditions
(Veldscholte et al. 1990). DU145 cells were derived from a brain metastasis of human
prostate cancer (Stone et al. 1978) and express both CK5 and CK8/18 cell surface
markers (Rahman, Miyamoto and Chang 2004). DU145 cells are androgen independent
and lack the expression of AR protein (Chlenski et al. 2001). PC3 cells were isolated
from a human prostate cancer bone metastasis (Kaighn et al. 1979) and they express both
CK5 and CK8 18 (van Bokhoven et al. 2003). As with DU145, PC3 cells are AR
negative and androgen-independent (van Bokhoven et al. 2003). PC3 cells have been
widely used to study androgen-independent prostate cancer or to study the role of AR in
androgen-independent cancer by transfection of a functional AR (Altuwaijri et al. 2007;
Yuanetal. 1993).
Igawa et al. (2002) established a LNCaP model to investigate the molecular
mechanism of androgen-independent growth of prostate cancer. Androgen-dependent
LNCaP parental cells were continuously maintained in phenol red-positive RPMI 1640
medium supplemented with 5% fetal bovine serum and 1% glutamine. Upon passage, the
androgen responsiveness of the cells decreased. The biological behavior of parental C-3 3
cells was altered. More aggressive growth and lower androgen responsiveness was
observed in later passages (C81) than in parental (C33). Both C-33 and C-81 express a
similar level of functional AR protein, however, in steroid-reduced culture conditions, C-
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81 cells secrete a higher level of PSA than C-33 cells. C-33 and C-81 together represent
a cell model that recapitulates the progression of human prostate cancer from the
androgen-dependent to the androgen-independent state under androgen deprived
conditions (Igawa et al. 2002).
H295R cells and JEG-3 cells are not prostate related; however, they are excellent
models for the study of steroidogenesis. H295R cells were originally cultured from an
adrenocortical carcinoma in a 48 year old African-American female (Gazdar et al. 1990).
They express all genes for steroidogenic enzymes found in all three layers of an adult
adrenal cortex (Staels et al. 1993; Rodriguez et al. 1997; Dardis and Miller 2003). The
JEG-3 cell line was cultured from a human choriocarcinoma. JEG-3 cells produce
progesterone and human chorionic gonadotropin (Chou 1982; Kato and Braunstein 1991;
Sun et al. 1998; Tremblay et al. 1999).
There are several different classes of in vivo animal models of prostate cancer
including transgenic and knockout mice, canine and rat models and xenografts (Sharma
and Schreiber 1999; Gruenewald et al. 1994). Transgenic models are either SV4O
transformed which include the TRAMP model that utilizes the minimal rat probasin
promoter to express the SV4O early genes as well as a number of transgenic lines using
the long probasin promoter which are categorized as the LADY model (Masumori et al.
2001). These two well characterized models display progressive disease from epithelial
hyperplasia to PIN to adenocarcinoma and development of metastasis (Masumori et al.
2001). Several germline knockout mice display prostate phenotypes including PTEN
heterozygous knockout mice, Nkx3.1 null and p27 null mice. The loss of these genes is






Clonetics® normal primary human prostate epithelial cells (PrEC) were obtained
from Lonza, Walkersville, MD. Prostate cancer cell lines DU 145, derived from brain
metastasis, PC3, isolated from a human prostate cancer bone metastasis with high
malignancy, and LNCaP-FGC, derived from a human prostate cancer lymph node were
obtained from American Type Culture Collection (ATCC; Manassas, VA). AR positive
derivatives of LNCaP cells, C33 (passage number less than 33) and C81 (passage number
higher than 81) cells were received from Dr. Lin (University of Nebraska). C8 1 cells
exhibit more aggressive growth and lower androgen responsiveness than C-33. LNCaP
cells gradually lose their androgen requirement for growth upon passage and therefore
represent an excellent in vitro cell model of prostate cancer progression (Igawa et al.
2002).
Cell Culture
DU145 and PC3 cells were cultured in Eagl&s minimum essential medium with
Earle’s salts and 0.1 mM of the following amino acid supplements: L-alanine, L
asparagine, L-aspartic acid, L-glutamic acid, L-proline, L-serine and L-glycine. The
medium also contained 4 mM L-glutamine, 2.5 g/l NaHCO3, 1.5 mM HEPES, 100 U/mi
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penicillin, 100 ug/mi streptomycin, 0.25 ug/ml amphotericin B and 50 jig/ml gentamicin.
LNCaP cells were routinely maintained in RPMI 1640 containing 1% glutamine, and
0.5% gentamicin. Both MEM and RPMI media (Mediatech, Hemdon, VA) were
supplemented with 5% fetal bovine serum (HyClone, South Logan, Utah) and kept at
37°C, under 5°o CO2.
RNA Isolation
TRIzol (Invitrogen, Carlsbad, CA) was used for the isolation of total RNA from
PrEC, DU145, PC3, C33 and C81 prostate cells following the manufacturer’s
instructions. Briefly, cells were lyzed directly in the culture dish by adding 500 ~.tl of
Trizol to a 3.5 cm2 diameter dish or 1 ml to a 10 cm2 diameter culture dish and scraping
forcibly with a sterile plastic cell scraper. The homogenate solution was transferred to a
1.5 ml microcentrifuge tube and incubated for 5 minutes at room temperature followed by
the addition of 200 jil of chloroform for every 1 ml of TRIzol. The tubes were shaken
vigorously by hand for 15 seconds then incubated at room temperature for 2 minutes.
The samples were centrifuged at 14,000 x g for 15 minutes at 4 C. Following
centrifugation, the colorless aqueous phase was transferred to a fresh microcentrifuge
tube and 500 p.1 of isopropyl alcohol per 1 ml of TRIzo1 used for initial homogenization
was added. Samples were incubated at room temperature for 2 minutes and centrifuged
at 14,000 x g for 30 minutes at 4 C. The supernatant was removed and 1 ml of 75%
ethanol was added to the RNA pellet and washed twice by centrifugation at 14,000 x g
for 5 minutes at 4 C. The RNA pellet was allowed to air-dry for 10 minutes. The RNA
was dissolved in RNase-free water and incubated for 10 minutes at 55 C. Two
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microliters of total RNA was added to 500 p3 of 10 mM Tris-HC1 (pH 8.0) for
quantitation. The optical density was measured at 260 nm and 280 nm, and the 260 280
ratio was calculated and used for quality assessment of RNA preparations. The purified
RNA was used immediately for RT-PCR or was stored at -80 C until analysis.
Protein Isolation
Total cell lysates were prepared from PrEC, DU145, PC3, C33 and C81 prostate
cells at densities of 70 — 80% confluence. The medium was removed and the cells were
washed twice with ice cold phosphate buffered saline (PBS), then lysed with cell lysis
buffer (Cell Signaling Technology, Beverly, MA) containing 20 mM Tris-HC1 (pH 7.5),
150 mM NaC1, 1mM Na2EDTA, 1mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1mM ~3-glycerophosphate, 1mM Na3VO4, 1~ig/ml leupeptin and lx
protease inhibitor cocktail (Calbiochem, San Diego, CA). The lysate was clarified by
centrifugation for 5 minutes at 14,000 x g at 4 C. After centrifugation, the supematant
was transferred to a new microcentrifuge tube. Total cell lysate samples were used
immediately or stored at -80 C.
Testosterone RIA
Cells were seeded in 6-well plates (106 cells/well) and cultured in serum free
medium for 48 hours, after which conditioned medium was collected and analyzed for
total androgens using a radioimmunoassay as described previously (Dickson et al. 2002).
Thin Layer Chromatography (TLC) Analysis
Cells were seeded in six well plates (106 cells/well) and incubated with 1 a, 2a
[N]-3H- Cholesterol (1 ~.tCi ml) in serum-free medium and incubated at 37°C for 48 hours
to determine if cells could convert radiolabeled cholesterol to radiolabeled testosterone.
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After 48 hours, the cells and media were extracted twice with chloroform/acetone (1:1,
v/v). The fractions were combined and dried at 76°C in a water bath, then subjected to
TLC on silica gel G plates and developed with chloroformldiethyl ether (1:1, v/v). The
silica gel plates were stained using phosphomolybdic acid then dried with a heat gun. On
heating, blue-black spots were visualized identifying the locations of the unlabeled
testosterone and cholesterol added to the mixture as standards. Spots were excised,
added to liquid scintillation fluid and radioactivity counted using a Beckman scintillation
counter (Schmidt et al. 2000; Schmidt et al. 2005).
Reverse Transcription - Polymerase Chain Reaction (RT-PCR)
The expression of mRNAs specific for steroidogenic proteins and enzymes were
determined by methods currently used in our laboratory. Total RNA was isolated from
PrEC, DU145, PC3, C33, and C81 cells as previously described. RNA isolated from two
established steroidogenic cells, adrenocarcinoma (H295R) and choriocarcinoma (JEG3)
cells were provided by Dr. Marion Sewer (Georgia Institute of Technology) and were
used as positive controls. Complementary DNA (cDNA) synthesis was carried out at
37 C for 90 minutes followed by 60 C for 10 minutes using 12 — 14 ~il of a master mix
containing the following: 5X RT buffer (Promega), 0.1 M dithiothreitol, 200 units of
MMLV Reverse Transcriptase (Promega), 10 mM DNTPs, and nanopure water
(Barnstedt). Samples were either used directly for PCR or were stored at -20 C until
analysis. PCR reactions were carried out with 1-3 p1 reverse transcription (RT) reaction
product using the primers outlined in Table 1. Gene-specific primers for all genes of
interest were designed using Vector NTI and Beacon Designer 4.0 software (table 1).
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The L19 gene was chosen as a housekeeping gene for inclusion in assays as an internal
standard. PCR products were analyzed by gel electrophoresis.
Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)
Quantitative differences in mRNA expression for StAR and CYP 17 between C33
and C8 1 cell lines were determined by Real-time PCR using an 1-Cycler Detection
System (Bio-Rad, Hercules,CA) in 96 well plates using a master mix containing the
following: 25 mM MgC12, 5 U/jil Taq DNA polymerase, lox SYBR Green, nuclease
free water and 1 ~.tg cDNA. The thermal cycling program on the 1-Cycler IQ was 30 cycles
consisting of 15 s incubation at 95° C and 1 mm incubation at 600 C. Melting curve
analyses were performed immediately following the final PCR cycle to differentiate
between the desired amplicons and any primer-dimers or DNA contamination. The
quantification of PCR results was accomplished by determining the Ct (the cycle at
which the fluorescence signal is first significantly different from background) for each
reaction. Ct values for each gene of interest were normalized by dividing with the Ct for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the endogenous control gene to
produce ACt. The difference between ACt values for a control and a test sample (AACt)
represents the degree of induction or inhibition of the gene of interest. Gene expression
was measured at least in triplicate for each sample and each gene quantification
experiment was repeated three times starting with independent cell treatments and results
were subjected to ANOVA statistical analysis.
Table 1
Primer Sequences for Qualitative and Quantitative PCR
GENE PRIMER SEQUENCES (5’-3’) PRODUCT(bp)
SCARB1 Forward AGGCATTGGACAAACTGGGAAG 296
Reverse TGTCATCAGGGATTCAGAATAGGC
StAR Forward ACCCGTTGGCTGGAAGTC 238
Reverse GATTCTCCTGATGAGCGTGTG
MLN64 Forward ATGAGCAAGCTGCCCAGGGA 306
Reverse GGCCAGGACAAAGATGTCGA
CYP1 1 Forward CGTCATTTTTGGGGAGCGCC 372
Reverse TGCAGGGTCATGGACGTCGT
3~-HSD Forward GGGCCCAACTCCTACAAGGA 356
Reverse ACTT’GGGGCCTI’CTTGGGGT
CYP 17 Forward AGCTCGTGGCTCTCTTGCTG 307
Reverse CGCGATGTCTAGAGTTGCCA
1713-HSD Forward GTGCTCATCACCGGCTGTTC 207
Reverse GGCCACGGATTTTGAGTCCC
CYPI9 Forward GCATCGGTATGCATGAGAAA 390
Reverse GCATCTTTCAAATCCTTGAC
L19 Forward GAAATCGCCAATGCCAACTC 405
Reverse TCTTAGACCTGCGAGCCTCA
GAPDH Forward GAAGGTGAAGGTTCGGAGTC 200
Reverse GAAGATGGTGATGGGATTTC
AR Forward TCGGAGGTCATCTGTTCCAT 272
Reverse AAGACCTTGCAGCTTCCACA
TMPRSS2 Forward TACGGACCAAACTTCATCCT 241
Reverse GAACAGGCATCACTGTGGTA
SRD5A2 Forward ACGGTACTTCTGGGCCTCTT 315
Reverse ACAAGCCACCTTGTGGAATC
PSA Forward TCATCCTGTCTCGGATTGTGG 295
Reverse GTGGCTGGAGTCATCACCTG
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Quantitation of Protein in Total Cell Lysates
DU145, PC3, LNCaPC33, LNCaPC81, and PrEC cells were grown to confluence
in 10 cm2 cell culture plates. Cells were washed with 5 ml of cold 1X phosphate buffered
saline (PBS). The PBS was removed by vacuum aspiration.
Cell lysis buffer was freshly prepared and 500 jil added to the cells. The cells were
scraped and total cell lysates added to a 1.5 ml microcentrifuge tube. Lysates were
centrifuged at 14,000 rpm at 4 C for 5 minutes and supernatants were collected and
stored at -80 C. The protein concentrations were determined by modified Lowery Assay
method using the BioRad DC protein assay kit in accordance with manufacturer’s
instruction. Briefly, 150 pi of Reagent A (an alkaline copper tartrate solution) was added
to each total cell lysate sample (5 ~.t1 of total cell lysate in 25 jil of nanopure water)
followed by the addition of 1.2 ml of Reagent B (Folin Reagent) and allowed to incubate
at room temperature. After 15 minutes, absorbance was read at 750 nm. A standard
curve was prepared each time the assay was performed using bovine serum as a standard.
Western Blot Analysis of Proteins
Protein expression of AR, StAR, MLN64, CYP1 1, CYP17, and 1713-HSD was
determined by Western blotting using total cell lysates obtained from PrEC, DU145,
PC3, C33, C81 and H295R cells. Total protein extracts (35 ~.tg) were electrophoresed on
10% polyacrylamide gels and the separated proteins were transferred onto polyvinylidene
difluoride membranes for immunodetection. Membranes were blocked in 5% nonfat dry
milk in 50 mM Tris-HC1, pH 7.5 and 0.1% Tween 20 (TBST) for 1 h at room temperature
and incubated with antibodies to AR, StAR, MLN 64 (Santa Cruz, CA), CYP1 1A, 3~3-
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HSD, and 1713-HSD overnight at 4 C, followed by horseradish peroxidase-conjugated
secondary anti-rabbit (BioSource) or anti-mouse (Sigma). Dr. Buck Hale of the
University of Southwestern Illinois generously provided human anti-StAR, anti-CYP
1 1A, and anti-1713-HSD sera. The anti-3 13-HSD was developed by Dr. Ian Mason
(Mason et al 1998) and provided to us by Dr. John Davis of the University of Nebraska
Medical Center, Omaha. Anti-13-Actin (Sigma, St. Louis, MO) was used as an internal
control. The signal was detected by chemiluminescence using the SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific, Rockford, IL). The relative intensities
of specific protein bands were determined by densitometric scanning of images using a
Typhoon Image Analysis System (GE Healthcare) and Quantity One Software (Bio-Rad,
Hercules, CA).
Cell Proliferation Assays
Cell proliferation was analyzed using the CeliTiter 96 Assay (MTT assay;
Promega, Madison, WI). The assay measures the cellular conversion of a tetrazolium salt
into a formazan product, which can be detected by spectrophotometry using a 96 well
plate reader. C-33 and C-81 cells were seeded into 96-well plates at a density of 5,000
cells/well in RPMI 1640 medium supplemented with 5% FBS for 48 hours. The medium
was replaced with phenol red-free RPMI 1640 supplemented with 5% charcoal dextran
treated FBS (CDS, Hyclone Laboratories) for 48 hours. Cells were treated with or
without 10 nM Ri 881 dissolved in ethanol (ethanol concentrations not exceeding 0.02%)
added at a concentration of 10 nM; 0.2mM aminoglutethimide; or 10 ~tM bicalutamide
dissolved in DMSO for 72 hours. The absorbance at 570 nm was measured with the Bio
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Tek Synergy HT (Bio-Tek Instruments, Winooski, VT). Five replicates per treatment
were assayed, and data averaged from three separate experiments are presented.
Apoptosis Assay
C81 cells were seeded in 10 cm2 cell culture dishes at a density of 106 cells/plate
in RPMI 1640 supplemented with 5% FBS for 48 hours. The medium was replaced with
phenol red-free RPMI 1640 containing 5% CSS for 48 hours. The cells were then treated
either with or without: 10 nM Ri 881; 0.2 mM aminoglutethimide; and/or 1 0~iM
bicalutamide for 72 hours. The cells were harvested and an assessment of apoptosis was
carried out using the Vybrant® Apoptosis Assay Kit (Molecular Probes, Eugene, OR)
according to the instructions provided by the manufacturer. The kit uses recombinant
annexin V conjugated to Alexa Fluor 488 dye to detect phosphatidylserine on the surface
of apoptotic cells which can be measured by flow cytometry. The kit also uses propidium
iodide for detection of dead cells. Samples were kept at room temperature and analyzed
immediately on a C6 Flow Cytometer with CFlow Plus Software (AccuriCytometers Inc.,
Ann Arbor, MI).
ELISA for PSA
C8 1 cells were seeded in 10 cm2 cell culture dishes at a density of 106 cells/plate
in RPMI 1640 supplemented with 5% FBS for 48 hours. The cells were then treated
either with or without: 10 nM Ri 881; 0.2 mM aminoglutethimide; and/or 1 0p~M
bicalutamide for 72 hours. Supernatants were collected for measurement of PSA using
an ELISA kit (Quantikine, R&D Systems, Minneapolis, MN). A 100 ~il sample was
added to a 96 well microplate precoated with a monoclonal antibody specific for PSA
followed by the addition of a polyclonal antibody conjugated to horseradish peroxidase
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specific for PSA. A substrate containing a color reagent was the added and the intensity
of color measured using a microplate reader. Color develops in proportion to the amount
of PSA bound by the monoclonal antibody.
Statistical Analysis
All results were confirmed in at least three independent experiments using
different cell preparations. Students “t” test and ANOVA were employed to assess if
there were significant differences between different cell lines and treatment groups.
CHAPTER 4
RESULTS
Expression of Steroidogenesis-associated Genes in Androgen-independent Prostate
Cancer Cell Lines
To investigate the potential of prostate cells in the advanced stages of the disease
to acquire the capability to synthesize androgens from cholesterol, we examined a normal
prostate cell line, PrEC, and the androgen-independent cell lines, DU145 and PC3, for
expression of the steroidogenesis-associated genes; SRB 1, StAR, CYP 11, 3 ~3HSD,
CYP 17, and 1 7I3HSD. RT-PCR analysis of the prostate cell lines along with two well
characterized steroidogenic cell lines, H295R adrenocarcinoma and JEG3
choriocarcinoma cells, was performed. The housekeeping gene, L19, was used as a
loading control. The steroidogenesis-associated genes involved in cholesterol uptake
(SRB1), its transportation to the inner mitochondrial membrane (StAR), conversion to
pregnenolone (CYP1 1) and subsequently to testosterone (313-HSD, CYP17 and 1713-
HSD), were expressed in all of the cell lines with the exception PrEC which did not
express CYP 17 (Figure 5). StAR, considered to be the rate limiting step in
steroidogenesis, was expressed at low levels in DU145 and PC3 and not at all in JEG-3


















Figure 5. RT-PCR expression of steroidogeneis-associated genes in (A) normal prostate
cells, PrEC, and (B) androgen-independent prostate cancer cells, DU145 and PC3.
Androgen Receptor Expression in Prostate Cancer Cells
Because androgen activity in the prostate gland is mediated by the androgen
receptor, we determined AR expression by RT-PCR and Western blot using mRNA and
total cell lysates extracted from C33, C81, DU145 and PC3 prostate cancer cell lines,
respectively. Androgen-dependent C33 and androgen-independent C81 cells were found
to express the AR transcript and protein while both DU145 and PC3 were negative for
AR transcript and protein expression (figure 6).
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Figure 6. AR expression in androgen-dependent C33 and androgen-independent, C81,
DU145, and PC3 prostate cancer cells (A) RT-PCR analysis of mRNA and (B) protein
expression by Western blot analysis.
Differential Expression of Steroidogenesis-associated Genes in an in vitro Prostate
Cancer Progression Model
In order to determine whether acquisition of complete steroidogenic capability by
prostate cancer cells is associated with progression from an androgen-dependent to an
androgen-independent state we analyzed expression of steroidogenesis-associated genes
in early passage androgen-dependent C33 and late passage androgen-independent C81
prostate cancer cells. These cell lines are AR positive and were established as an in vitro
model of prostate cancer progression from androgen dependence to an androgen
independent state. We analyzed transcript expression of SRB1, StAR, CYP1 1, 3~3-HSD,
CYP17 and 1713-HSD using RT-PCR (figure 7). H295R and JEG3, known steroidogenic
cells, were included as controls to ensure the specificity of the primers. We detected all
of the components of steroidogenic machinery in C81 cells however we were not able to
detect the expression of CYP 17 in C3 3 cells. Qualitative expression of StAR in C8 1 cells
was significantly higher than was seen in the C33 cells.
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Figure 7. Differential expression of steroidogenesis-associated genes in androgen
dependent C33 and androgen-independent C81 prostate cancer cells.
Quantitative Expression of StAR in C33 and C8 1 Prostate Cancer Cells by Real-Time
RT-PCR
To further evaluate the differential expression of StAR in C33 and C81 prostate
cancer cells, we performed quantitative real-time RT-PCR. Results were normalized to
GAPDH and in a representative experiment (figure 8) we demonstrated that there is 4
fold higher expression of StAR in late passage androgen-independent C8 1 compared with


















Figure 8. Quantitative real-time RT-PCR analysis of StAR expression in C33 and C81
prostate cancer cells normalized to GAPDH.
Confirmation of StAR Expression by Sequence Analysis
Since expression of StAR in the prostate has not been previously reported we
excised the RT-PCR product identified as StAR and sent it to the Morehouse School of
Medicine (Atlanta, GA) DNA Sequencing Facility for determination of nucleotide
sequences of the PCR product. We performed a NCBI blast analysis of the sequencing
data received from Morehouse which confirmed that the RT-PCR product that we
identified as Star exhibited 99% homology with human StAR (figure 9).
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Figure 9. Homology of RT-PCR product with human StAR.
Protein Expression of StAR, CYP 11, and CYP 17 in Prostate Cell Lines
We performed Western blot analysis to determine expression of selected
steroidogenesis-associated proteins and enzymes. StAR is required for the transport of
cholesterol to the inner mitochondrial membrane and this action is considered to be the
rate limiting step in steroidogenesis. CYP 11 resides on the inner mitochondrial
membrane and is responsible for the initial enzymatic reaction that cleaves the side chain
and converts cholesterol to the steroid precursor, pregnenolone. The results of Western
blot analysis of total cell extracts from PrEC, C33, C81, DU145 and PC3 cells for StAR
and CYP1 1 are shown in figure 10. Cell lysates from H295R cells were used to validate
specificity of the antibodies and ~3-Acting as a loading control. Although the StAR
transcript was expressed we did not detect any protein expression in PrEC cells. CYP 11
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protein expression was present in all of the prostate cell lines. Another critical enzyme in
testosterone biosynthesis is CYP 17 which is required for the metabolism of
pregnenolone to androstenedione and essential for androgen production. Since we did not
detect CYP 17 mRNA transcripts in all the cell lines by RT-PCR, we performed Western
blot analysis to investigate CYP17 protein expression C33, C81, DU145 and, PC3
prostate cancer cells (figure 11). C33 cells did not show expression of CYP17 which is
consistent with RT-PCR data showing lack of transcript expression of CYP17.




Figure 10. Expression of key components of steroidogenesis, StAR and CYP 11, in
prostate cell lines by Western blot analysis.
C33 C81 DU145 PC3
CYP17
f3-Actin
Figure 11. Western blot analysis of CYP 17 protein expression in prostate cancer cell
lines.
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Testosterone Synthesis in Prostate Cancer Cells
Once we had determined that all of the components of steroidogenic machinery
were present in prostate cancer cells we wanted to investigate whether these cells could,
in fact, synthesize testosterone. We cultured androgen-dependent C33 and androgen
independent C8 1 prostate cells in serum-free culture media for 48 hours. The
conditioned media were collected and analyzed for the presence of androgens by
radioimmunoassay (figure 12). Although androgens were detected in the conditioned
media of both cells lines, the quantity of androgens produced by C8 1 cells was much
















Prostate Cancer Cell Lines
Figure 12. Androgen detection in C33 and C81 cells by RIA.
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Prostate Cancer Cells Can Synthesize Testosterone From Cholesterol
To investigate whether or not C33 and C8 1 prostate cancer cells can transport
cholesterol from serum and convert it into androgens, we determined the conversion of
labeled cholesterol to testosterone in these cells. C33 and C81 cells were cultured in the
presence of lci~, 2a [N] - 3H-cholesterol (li.tCi/ml, 34 jiM) for 48 h in phenol red-free and
serum-free medium. The conditioned media and cell extracts were then analyzed for the
presence of labeled testosterone by TLC. Figure 13 contains a representative silica gel
plate showing separation of testosterone and cholesterol fractions separated by TLC.
Cholesterol and testosterone standards were applied to the TLC plate for comparison with
the samples being analyzed. Testosterone and cholesterol were visualized on the plate as
black dots and the areas on the TLC plate corresponding to testosterone were scraped,
placed in liquid scintillation fluid, and analyzed using a scintillation counter (figure 14).





Figure 13. Representative thin layer chromatogram of C33 and C81 conditioned media
and cell extracts. Cholesterol (CR) and testosterone (TE) standards were applied to the




















Prostate Cancer Cell Lines
Figure 14. Scintillation counter measurement of testosterone synthesized from 3H-
cholesterol.
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Effects of Endogenously Synthesized Testosterone on Proliferation of C8 1 Prostate
Cancer Cells
We have shown that androgen-independent C8 1 prostate cancer cells express AR,
contain all of the steroidogenic machinery and synthesize testosterone from cholesterol.
The second aim of this investigation was to determine if endogenous testosterone is
required for the survival and growth of prostate cancer cells. To do this we treated
steroidogenic C8 1 cells with aminoglutethimide to prevent conversion of cholesterol to
pregnenolone and with the AR antagonist bicalutamide for 72 hours and measured cell
proliferation using the MTT Assay (figure 15). Aminoglutethimide and bicalutamide
treatments inhibited the growth of C8 1 cells and this inhibition was reversed by the













Control R1881 AMG AG+R1881 BC BC+R1881
Treatment
Figure 15. Effects of aminoglutethimide (AG) and bicalutamide (BC) treatments on
proliferation of C8 1 prostate cancer cells.
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The Effects of Endogenously Synthesized Testosterone on C8 1 Prostate Cancer Cell
Survival
To determine if inhibition of endogenous testosterone production would reduce
survival in prostate cancer cells through the induction of apoptosis, we treated C8 1 cells
with or without aminoglutethimide, bicalutamide and in the presence or absence of
Ri 881 for 3 days. Alexa-Fluor labeled Annexin V and propidium iodide were added to
the cells and flow cytometry was performed to measure the binding of phosphatidyl
serine by fluorescent labeled Annexin V (figure 16). Aminoglutethimide did increase
apoptosis in C8 1 prostate cancer cells with or without Ri 881; however, there was a
significant increase in apoptosis with bicalutamide treatment alone. The percentage of










Control R1881 AG AG+R1881 BC BC+R1881
Treatment
Figure 16. Apoptosis in C8 1 prostate cancer cells treated with aminoglutethimide (AG)
and bicalutamide.
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Effects of Endogenously Synthesized Androgens on AR Regulated Gene Expression in
C8 1 Prostate Cancer Cells
To investigate the involvement of AR in the biological effects of endogenously
produced androgens, we looked at mRNA and protein expression of the well established
AR regulated genes, PSA and TMPRSS2. C8 1 cells were treated with or without
aminoglutethimide, bicalutamide, and in the presence or absence of Ri 881. RNA and
total cell lysates were extracted and analyzed by PCR and Western blot respectively.
PSA and TMPRSS2 transcript expressions were significantly reduced in the
aminoglutethimide and bicalutamide treated C81 cells (figure 17). There was a
restoration of transcript expression level in aminoglutethimide and bicalutamide treated
cells in the presence of Ri 881. Expression of PSA was not detected by western blot
analysis.
AG - + + - -
DHT + - + - +




Figure 17. Differential expression of AR regulated genes in C8 1 cells after treatment
with aminoglutethimide (AG), bicalutamide (BC), and DHT for 48 hours.
59
The Effects of Inhibitors of Androgen Signaling on PSA Secretion
C8 1 cells were treated with aminoglutethimide, bicalutamide and/or Ri 881 for 72
hours in serum-free culture medium. Conditioned media was collected and PSA was
measured using ELISA. PSA secretion was inhibited by treatment of C8 1 with
aminoglutethimide and bicalutamide however; this inhibition was reversed by treatment








Figure 18. Effects of aminoglutethimide and bicalutamide treatment on PSA secretion in
C8 1 prostate cancer cells by ELISA.
CHAPTER 5
DISCUSSION
Mohier and collaborators (2004) reported the presence of significant amounts of
testosterone and DHT in recurrent prostate cancer tissues, enough for the activation of
AR and suggested that prostate cancer cells may synthesize androgens from adrenal
precursors or cholesterol. Expression of all of the steroidogenic enzymes necessary to
convert the adrenal androgens, DHEA and androstenedione, into testosterone and DHT
have been previously reported in the human prostate. It has been hypothesized by several
investigators that adrenal androgens provide a source to explain the findings of androgen
levels in recurrent cancer following androgen ablation therapy sufficient to activate the
AR. The enzyme, 3 13-HSD, that converts DHEA into androstenedione and 1713-HSD
which is required for the conversion of androstenedione to testosterone have both been
shown by in situ hybridization to be expressed in the prostate (El-Alfy et a!. 1999). The
enzyme needed for the metabolism of testosterone to DHT, 5a-reductase, is also
expressed in the prostate (Prins et a!. 1992; Titus et al. 2005). These results indicate that
prostate cells are able to synthesize androgens from adrenal precursors. Our studies
support the notion that testosterone may be synthesized from cholesterol in the prostate.
This possibility is also supported by a study showing upregulation of genes associated
with cholesterol biosynthesis in androgen ablation resistant prostate tumors
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(Holzbeierlein et a!, 2004) suggesting that prostate cancer cells may be able to increase
biosynthesis of intracellular cholesterol to support steroidogenesis.
In this study, we have reported for the first time that all of the key components of
steroidogenic machinery required for cholesterol uptake, cholesterol transport into the
inner mitochondrial membrane and the enzymes required for conversion of cholesterol to
pregnenolone and subsequently to testosterone are expressed in androgen independent
prostate cancer cell lines and that they are capable of synthesizing testosterone from
cholesterol. A normal prostate epithelial cell line, PrEC, and two well characterized
androgen independent prostate cancer cell lines, DU 145 and PC3 were initially employed
to study steroidogenesis-associated gene expression. As a first step towards determining
the complete steroidogenic capability of these prostate cell lines we examined the
expression of genes involved in cholesterol uptake and transport into the inner
mitochondrial membrane which is the rate limiting step in steroidogenesis. RT-PCR
analyses revealed the strong expression of SRB 1 in all three prostate cell lines; however,
expression of StAR was detected at a low level in these cells compared with the well
characterized steroidogenic H295R adrenocarcinoma cell line (Gazdar et al. 1990; Staels
et al. 1993; Rodriguez et al. 1997; Dardis and Miller 2003). JEG3 is a steroidogenic
choriocarcinoma cell line that does not express StAR but utilizes another START family
member, MLN64 for cholesterol transport into the mitochondria (Chou 1982; Kato and
Braunstein 1991; Sun et al. 1998; Tremblay et al. 1999). Once we had established the
expression of the rate limiting StAR we expanded our RT-PCR analyses to include the
enzymes, CYP1 1, 313-HSD, CYP17 and, 1713-HSD, involved in converting cholesterol
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into testosterone. We observed the expression of all the requisite steroidogenic enzymes
in the androgen-independent DU145 and PC3 but we found that PrEC as well as JEG3
lacked expression of CYP 17 which is required for the conversion of progesterone to
androstenedione. Since placental cells primarily metabolize progesterone there is not a
need for enzymes that metabolize components downstream of progesterone therefore
CYP17, which converts pregnenolone to androstenedione, is not needed in this cell line
(Chou 1982). All three cell lines expressed comparable levels of 1713-HSD1 which was
confirmed by sequencing the PCR product. The expression of several isoforms of 1 7~3-
HSD has been reported in the prostate (Labrie et al. 1997; Takase et al. 2006).
To determine whether the expression of steroidogenic machinery correlates with
the development of independence from exogenous testosterone, we employed an LNCaP
progression model that consisted of androgen-dependent (C33) and androgen
independent (C8 1) cell lines which represent this phenomenon in vitro. We confirmed
the presence of AR mRNA and protein in C33 and C81 cells and the absence of AR
expression in DU145 and PC3 cells. The presence of AR makes C33 and C81 a better
model for these studies. We determined the expression of all steroidogenic associated
genes in C33 and C8lcells by RT-PCR. All key components of steroidogenic machinery
are expressed in androgen independent C81 cells. Both C33 and C81 cells expressed
SRB1, P45Oscc, 3~3HSD and 17f3HSD at comparable levels; however StAR expression
was low in C33 cells compared to C81 and no expression of CYP17 was detected in C33
cells. These results were confirmed using Western blot analysis. StAR protein was not
detected in PrEC cells and is present at low levels in C33 cells. C81 cells contained
63
higher (4-fold) amount of StAR protein when compared with C33 cells. We also
detected the presence of StAR protein in PC3 and DU145 cells. As seen with RT-PCR,
Western blot analysis also failed to detect CYP17 in C33 cells while detectable levels of
this key enzyme were present in C81, DU145 and PC3 cells. Since StAR is critical for
cholesterol transport into mitochondria and CYP17 is required for androgen synthesis
from progesterone, C33 cells may have very low or limited capacity to synthesize
androgen from cholesterol and therefore would be dependent upon exogenous sources of
testosterone for its survival. These studies have been supported by the findings of others
showing the expression of steroidogenesis-associated genes in castration resistant
prostate tumors (Locke et al. 2008; Montgomery et al. 2008; Stigliano et al. 2007).
These data suggest that androgen independence in prostate cancer cell lines
correlates with the acquisition of proteins and enzymes required for androgen
biosynthesis from cholesterol. To determine that prostate cancer cells can synthesize
testosterone from cholesterol we used RIA to measure testosterone levels in conditioned
media using RIA. We found that detectable levels of testosterone were present in the
conditioned media from C33 and C8 1 cells. However, C8 1 cells secreted five-fold higher
testosterone than C33 cells. No detectable levels of testosterone were found in the
conditioned media from PC3, DU145, HeLA, and COS cells (data not shown). These
data show that androgen independence is indeed associated with biosynthesis of
testosterone by C8 1 cells in the absence androgens from exogenous sources. The reason
for undetectable levels of testosterone in conditioned media from PC3 and DU 145 cells
could be due to low production of testosterone by these cells as a consequence of low
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expression of StAR or other proteins, or by aromatization of testosterone to estradiol by
the enzyme, CYP 19. This later possibility is supported by high expression of aromatase
in these cell lines (Elem et a!, 2004). It is possible that androgens may be irrelevant in
these cell lines since they do not express AR.
To further confirm that C33 and C81 cells are capable of using cholesterol uptake
and its conversion into androgens, we utilized TLC to analyze the conditioned media
from 1 a, 2a [N] - 3H-cholesterol treated cells for the presence of labeled testosterone. We
detected radioactive testosterone in extracts from both C33 and C8 1 cells. Since
radioactive testosterone could only be synthesized from radioactive cholesterol, this
experiment conclusively demonstrated that prostate cancer cells are capable of making
androgens from exogenous cholesterol. We did not detect any radioactive testosterone in
DU145 and PC3 cells confirming the results we obtained by RIA. The finding that
androgen-independent prostate cancer cells can synthesize androgens from cholesterol
has been supported by a recent study in which castration resistant LNCaP xenograft cells
were shown to convert [‘4C] acetic acid to DHT (Locke et al. 2008).
Androgens are required for the survival and growth of prostate cells. We
investigated the role of endogenously synthesized androgens on survival and growth of
prostate cancer cells. We measured cell proliferation in steroidogenic C8 1 cells treated
with either aminoglutethimide, which prevents the cleavage of cholesterol to
pregnenolone, or bicalutamide, an AR antagonist. The MTT assay showed that both
aminoglutethimide and bicalutamide had inhibitory effects on cell proliferation that could
be reversed in the presence of exogenous DHT. Our results show that endogenously
65
produced androgens promote cell growth in C81 cells in a manner similar to exogenously
supplied DHT. Growth inhibition by aminoglutethimide treatment alone did not promote
apoptosis in C8 1 cells however, treatment with bicalutamide resulted in significant
apoptosis when analyzed by flow cytometry for the detection of fluorescent labeled
annexin V attachment to membrane phosphatidylserine in cells undergoing apoptosis.
Since the activity of androgens are mediated through AR, we performed PCR to
investigate the transcript expression of two well established AR regulated genes, PSA
and TMPRSS2, in C81 prostate cancer cells treated with either aminoglutethimide or
bicalutamide. PSA and TMPRSS2 mRNA expression were decreased in both the
aminoglutethimide and bicalutamide treated cells, however, when exogenous DHT was
supplied transcript expression for both genes was restored. Measurable levels of PSA by
Western blot were not detected for C8 1 cells treated with or without aminoglutethimide,
bicalutamide or DHT. Measurement of PSA levels in conditioned media by ELISA
showed that aminoglutethimide and bicalutamide treatment decreased PSA secretion but
this inhibition could be reversed by the addition of DHT. Androgens synthesized from
cholesterol by the prostate are shown here to be involved in survival and proliferation of
androgen-independent C8 1 prostate cancer cells in vitro and that AR is essential to the
exertion of the biological effects observed in these cells.
CHAPTER 6
CONCLUSION
In conclusion, we have demonstrated that prostate cancer cells in the advanced
stages of the disease acquire complete steroidogenie ability to synthesize androgens from
cholesterol and this may represent a mechanism by which prostate cancer cells are able to
survive and proliferate in a castration level androgen environment. Our results further
underline the fact that castration and inhibition of testosterone production in the testes
may not achieve androgen deficiency in the recurrent stages of the disease. We have
confirmed the essential role of AR in the survival and proliferation of castration resistant
prostate cancer cells consistent with the findings of others and suggest that inhibitors of
steroid biosynthesis in prostate cancer cells may be required to completely abolish the
androgens in these tumors. Recently a clinical trial of a compound targeting CYP 17 has
been undertaken (Montgomery et al. 2008). The results of this study suggest that the
steroidogenesis pathway offers a number of potential therapeutic targets for castration
resistant prostate cancer. MLN64 is of special interest since it was first identified in
metastatic breast cancer and has been shown to be expressed in prostate cancer cells
(Stigliano et al. 2008). Further studies are needed to determine the molecular
mechanisms involved in the transition of androgen dependent (plasma and adrenal
precursors) prostate cancer cells to a phenotype with the complete capability of
intraprostatic androgen biosynthesis. There are a few studies reporting the presence of
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LH, hCG, and ACTH receptors in the prostate and it will be important to elucidate the
regulation of endogenous prostate androgen biosynthesis (Dirnhofer et a!. 1998; Tao et al.
1997; O’Shaughnessy et al. 2003). Although androgen signaling is the most investigated
area of prostate research the findings reported here of intracrine regulation of AR
provides the opportunity to explore another aspect of androgen action that may finally
offer answers to the questions of why growth of the prostate gland resumes in late
adulthood following four decades of quiescence and, can the failure of androgen ablation
therapy be prevented?
Aromatization of testosterone by CYP 19 within the prostate and the role of
estrogen in castration resistant prostate cancer should not be ignored. Prostate cancer
cells express CYP 19 (Ellem et a!. 2004) and can synthesize estrogens which could
explain the presence of the full steroidogenic machinery in androgen-independent DU145
and PC3 prostate cancer cells that have been shown to express estrogen receptors but not
AR.
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